Brain tissue salvage in acute stroke

Neurocritical Care

Volumn 1, Issue 3, 2004, Pages 301-308

  Lindsberg, Perttu J ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b BIOMEDICUM HELSINKI   (Finland)

Author keywords

Brain ischemia; Neuroprotection; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; ANTIHYPERTENSIVE AGENT; CITICOLINE; DIZOCILPINE; FIBRINOLYTIC AGENT; GLUCOSE; LUBELUZOLE; NIMODIPINE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; STREPTOKINASE;

BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; BODY TEMPERATURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TISSUE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG FATALITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOCYTOSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECANALIZATION; REVIEW; RISK FACTOR; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HUMANS; NEUROPROTECTIVE AGENTS; THROMBOLYTIC THERAPY; TISSUE SURVIVAL;

EID: 24644468171     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1385/NCC:1:3:301     Document Type: Review

References (70)

1. Sandercock P. Managing stroke: the way forward. Br Med J 1994;307:1297-1298.
2. Stroke Unit Trialists' Collaboration. Collabor-ative systematic review of the randomized trials of organised inpatient (stroke unit) care after stroke. Br Med J 1997;14:1151-1159.
3. Kaste M. Thrombolysis in ischaemic stroke-present and future: role of combined therapy. Cerebrovasc Dis 2001;11(Suppl 1):55-59.
4. Wardlaw JM. Overview of Cochrane thrombolysis meta-analysis. Neurology 2001;57(Suppl 2):S69-S76.
5. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017-1025.
6. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
7. Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251.
8. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-2026.
9. Adams HP Jr., Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 1996;27:1711-1718.
10. Grotta JC, Burgin S, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-2013.
11. Merino JG, Silver B, Wong E, et al. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke 2002;33:141-146.
12. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study. JAMA 2000;283:1145-1150.
13. Hill MD, Buchan AM for the CASES investigators. CASES: final results. CCNS Meeting June 2002, Vancouver. Can J Neurol Sci 2002;29:S34.
14. Lindsberg PJ, Soinne L, Roine RO, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003;34:1443-1449.
15. Lindsberg PJ, Kaste M. Thrombolysis for ischemic stroke. Curr Opin Neurol 2003;16:73-80.
16. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-775.
17. Warlow C, Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. What is good for heart attacks is still not good enough for brain attacks. Br Med J 2003;326:233-234.
18. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
19. Els T, Klisch J, Orszagh M, et al. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovasc Dis 2002;13:89-94.
20. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. Neurology 2002;59:669-674.
21. Demchuk AM, Tanne D, Hill MD, et al. The Multicentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001;57:474-480.
22. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PAstroke survey. Circulation 2002;105:1679-1685.
23. Morikawa S, Inubushi T, Ishii H, et al. Effects of blood sugar level on rat transient focal brain ischemia consecutively observed by diffusion-weighted EPI and (1)H echo planar spectroscopic imaging. Magn Reson Medic 1999;42:895-902.
24. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. Blood pressure response to glucose potassium insulin therapy in patients with acute stroke with mild to moderate hyperglycaemia. J Neurol Neurosurg Psychol 2001;70: 401-404.
25. Jörgensen HS, Nakayama H, Raaschen HO, Olsen TS. Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344: 156-159.
26. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology 1993;43:461-467.
27. Adams HP Jr., Brott TG, Crowell RM,, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for Healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994;25:1901-1914.
28. The European Ad Hoc Consensus Group. Optimizing intensive care for stroke. Cerebrovasc Dis 1997;7:113-128.
29. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. IST Collaborative Group. Blood pressure and clinical outcomes in the international stroke trial. Stroke 2002;33:1315-1320.
30. Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000;31: 1250-1255.
31. Bogousslavsky J, Victor SJ, Salinas EO, et al. European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 2002;14:239-251.
32. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000;343:710-722.
33. Bath P, and the ENOS investigators. Efficacy of nitric oxide in stroke (ENOS) trial - a prospective randomised controlled trial in acute stroke. Ongoing Clinical Trial Abstract presented in 28th Annual International Stroke Conference, Phoenix, AZ, February 13, .2003.
34. Ginsberg M, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998;29:529-534.
35. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996;347:422-425.
36. Kammersgaard LP, Jorgensen HS, Rungby JA,, et al. Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen stroke study. Stroke 2002;33: 1759-1762.
37. Lyden P, Nd K, Al-Senani F,, et al. Phase 1 study of endovascular-induced hypothermia in patients with acute ischemic stroke [abstract]. Stroke 2003;34:249.
38. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-556.
39. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-563.
40. Knoll T, Wimmer ML, Gumpinger F, Haberl RL. The low normothermia concept - maintaining a core body temperature between 36 and 37°C in acute stroke unit patients. J Neurosurg Anesthesiol 2002;14:304-308.
41. Georgiadis D, Schwarz S, Evans DH, Schwab S, Baumgartner RW. Cerebral autoregulation under moderate hypothermia in patients with acute stroke. Stroke 2002;33:3026-3029.
42. Georgiadis D, Schwarz S, Schwab S. Endovas-cular cooling for moderate hypothermia in patients with acute stroke. First results of a novel approach. Stroke 2001;32:2550-2553.
43. Heiss WD, Forsting M, Diener HC. Imaging in cerebrovascular disease. Curr Opin Neurol 2001; 14:67-75.
44. Parsons MW, Barber A, Chalk J, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37.
45. Lev MH, Farkas J, Rodriguez VR, et al. CT angiography in the rapid triage of patients with hyperacute stroke to intraarterial thrombolysis: accuracy in the detection of large vessel thrombus. J Comput Ass Tomogr 2001;25:520-528.
46. Alexandrov A. Presentation of CLOTBUST trial results. 29th International Stroke Conference. San Diego, July 2, 2004.
47. Lev MH, Segal AZ, Farkas J, et al. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis. Prediction of final infarct volume and clinical outcome. Stroke 2001;32:2021-2028.
48. Suarez JI, Zaidat OO, Sunshine JL, et al. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes. Neurosurgery 2002;50:251-260.
49. Warach S. New imaging strategies for patient selection for thrombolytic and neuroprotective therapies. Neurology 2001;57(Suppl 2):S48-S52.
50. Heiss W-D, Thiel A, Grond M, Graf R. Which targets are relevant for therapy of acute ischemic stroke? Stroke 1999;30:1486-1489.
51. Lindsberg PJ, Roine RO, Tatlisumak T, Sairanen T, Kaste M. The future of stroke treatment. Neurol Clin 2000;18:495-510.
52. Buchan AM, Slivka A, Xue D. The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res 1992;574:171-177.
53. Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354.
54. Horn J, de Haan RJ, Vermeulen M, Limburg M. Very early nimodipine use in stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 2001;32:461-465.
55. RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-1458.
56. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology 2001;57:1428-1434.
57. Vuorte J, Lindsberg PJ, Kaste M, et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol 1999;162:2353-2357.
58. Hacke W, Lees KR, Krams M, for the ASTIN Study Group. An adaptive dose response finding study of UK-279,276 in acute ischemic stroke [abstract]. Stroke 2003;34:248.
59. Diener HC, Cortens M, Ford G, et al. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-2551.
60. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE, and the Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595-1602.
61. Nakatomi H, Kuriu T, Okabe S, et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 2002;110:429-441.
62. Li Y, Chen J, Chen XG, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002;59: 514-523.
63. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999;282:2003-2011.
64. Cintas P, Le Traon AP, Larrue V. High rate of recanalization of middle cerebral artery occlusion during 2-MHz transcranial color-coded doppler continuous monitoring without thrombolytic drug. Stroke 2002;33:626-628.
65. Lutsep HL. Mechanical thrombolysis in acute stroke. eMedicine. Available at: http://www.emedicine.com/neuro/topic70htm. Accessed September 20, 2002.
66. Ringleb PA, Schellinger PD, Schranz C, Hacke W. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful? Stroke 2002;33:1437-1441.
67. von Kummer R, Allen KL, Holle R, et al. Acute stroke: usefulness of early CT findingsbefore thrombolytic therapy. Radiology 1997;205: 327-333.
68. Lindsberg PJ and Kaste M. Thrombolysis for acute stroke. Curr Opin Neurol 2003;16:73-80.
69. Lindsberg P and Roine RO. Hyperglycemia in acute stroke. Stroke 2004;35:363-364.
70. Krams M, Lees KR, Hacke W, et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003;34:2543-2548.